Objectives: To identify the frequency of micafungin resistance among clinically significant isolates of Candida stored at our institution from 2005 to 2015. Chart review of patients with resistant isolates then informed the clinical setting and outcomes associated with these infections.
Introduction
Candidaemia and non-candidaemic invasive candidiasis are important causes of nosocomial infections in the USA. 1 In addition to being associated with excessive mortality, an area of particular concern is the emergence of antifungal-resistant Candida isolates, especially those that are resistant to multiple agents, including the antifungal azoles and the echinocandins. [2] [3] [4] [5] These MDR Candida strains represent a major challenge to effective management of this common healthcare-associated infection.
Echinocandin resistance has been reported from several individual sites and large surveys of candidaemia. Single-centre studies are showing some concern regarding an increasing frequency of echinocandin resistance occurring as well as a trend towards worse outcomes in those patients with bloodstream infections due to echinocandin-resistant Candida. [2] [3] [4] [5] [6] [7] There are far fewer data regarding outcomes associated with non-candidaemic invasive candidiasis, although anecdotal reports suggest poorer outcomes in the setting of intra-abdominal disease. 8, 9 Rates of echinocandin resistance range from 1% to 13% in published reports. Resistance is usually mediated via point mutations in the genes encoding the FKS1 and FKS2 subunits of the glucan synthase protein. 10, 11 Phenotypic resistance, as measured by MIC, and genetic mutations generally occur concurrently but not always. Discordant azole resistance and echinocandin resistance are reported frequently among Candida glabrata isolates, but resistance and genetic mutations have been reported across multiple, clinically relevant species. With rates of azole resistance among C. glabrata isolates approaching 20%-30% in some surveys, there is a greater likelihood of dual resistance to both azoles and echinocandins.
Based on the aggregate results of large prospective randomized trials, echinocandins are considered first-line therapy for most cases of candidaemia and are generally recommended for empirical treatment of suspected invasive candidiasis. 12, 13 Unfortunately, there are no prospective data on the optimal management of echinocandin-resistant Candida infections and the emergence of these organisms presents a unique and difficult challenge to clinicians managing these infections. Here, we screened for phenotypic and genotypic resistance to micafungin in 3876 clinically significant Candida isolates collected over 11 years from a single institution and describe the outcomes of patients with echinocandin-resistant isolates following treatment.
Materials and methods
Clinical isolates of Candida spp. had been stored at #80 C in Brucella broth with 20% glycerol at the University of Alabama at Birmingham from 2005 to 2015. These isolates were recently tested using broth microdilution (CLSI M27-A3 and CLSI M27-S4) to determine MICs of micafungin. 14, 15 Micafungin resistance testing was not being performed as part of clinical routine during the study period; all testing described here was performed retrospectively. As such, this information was not available to treating physicians at that time. Additionally, all C. glabrata isolates and other isolates with decreased susceptibility were submitted to the CDC for genetic sequencing of FKS1 and FKS2. We reviewed the charts of all patients with a positive culture for C. glabrata with decreased susceptibility to micafungin and/or a mutation in an FKS gene.
C. glabrata isolates were initially screened for the presence of FKS mutations in hotspot 1 of the FKS1 and FKS2 genes using a Luminex assay, as previously described. 16 For any isolate that was determined to be non-WT by the Luminex assay, the hotspot 1 region of the FKS1 and FKS2 genes were sequenced to confirm the mutation. 11 Because previous surveillance revealed an exceedingly low level of hotspot 2 mutations in C. glabrata, the hotspot 2 regions of FKS1 and FKS2 were not sequenced.
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Results
We identified and tested 3876 Candida isolates collected from 2005 to 2015. The most common species seen were: 1921 Candida albicans, 832 C. glabrata, 508 Candida parapsilosis, 405 Candida tropicalis, 88 Candida krusei, 43 Candida guilliermondii and 20 Candida lusitaniae. There were 33 isolates that demonstrated decreased susceptibility to micafungin and/or had an FKS mutation. The isolates were collected from 31 unique patients. There were 15 isolates from the blood, 10 isolates from abdominal fluid, 5 isolates from urine, 2 isolates from lungs and 1 isolate from an intravascular catheter tip. Two patients had concurrent isolates from both blood and abdominal fluid. The first resistant isolate was identified in 2007. The overall trend for candidaemia rates can be seen in Figure 1 . Among the 15 blood isolates, 12 were identified as C. glabrata, 2 as C. tropicalis and 1 as C. lusitaniae. Among the candidaemia patients, there were 9 deaths (60%) at 30 days from the time of blood culture collection. Five of the isolates (33%) demonstrated an MIC in the susceptible range but had an FKS mutation. Two isolates had an intermediate MIC with one of those having an FKS mutation. The remaining eight isolates (53%) had resistant MICs ranging from 0.25 to .16 mg/L with only two having an FKS mutation. Treatment information was available for 13 patients. Of those, 12 received micafungin and only one received fluconazole.
The median age of patients with a resistant isolate was 43 (range " 22-84). Most patients were white (60%) and female (60%), and most were receiving total parenteral nutrition, had been on broad-spectrum parenteral antibacterial agents and had received an echinocandin in the preceding 3 months. Further details of this group can be seen in Table 1 .
Sixteen resistant isolates were from sources other than blood. Two of these isolates were from a pulmonary/airway source and were deemed insignificant and not examined in conjunction with clinical outcome. The remaining resistant isolates included Trends over time for candidaemia and echinocandin-resistant infections at our institution can be seen in Figure 1 . During the course of the study period, we observed a trend towards decreased numbers of cases of candidaemia annually. Infections involving micafungin-resistant Candida isolates have remained low throughout the study period. Overall, micafungin resistance was seen in 1.2% of all candidaemia isolates during the years 2008 to 2015, the highest year being 2014 with 4.7% echinocandin-resistant isolates.
Discussion
Antifungal resistance in Candida infections, especially resistance to echinocandins, is an increasing concern. Based on reports of echinocandin resistance in C. glabrata, coupled with the emergence of Candida auris, it is becoming increasingly important to understand local resistance patterns. As part of developing this background information at our institution, we found uncommon and sporadic resistance without a clear upward trend.
Prior therapy with an echinocandin is the primary reported risk factor for developing a candidaemia with an echinocandinresistant strain of Candida. 2, 5 However, a large multicentre study designed to better understand the impact of antifungal resistance on outcomes is a critical need. Moreover, there are few published data on the outcomes of non-candidaemic invasive candidiasis due to echinocandin-resistant organisms. Further studies are also required in this syndrome to more fully understand its frequency and impact on clinical and mycological outcomes.
Increasing antifungal resistance has been demonstrated at multiple institutions similar to ours and it is unclear why we did not observe a similar trend. The consistent risk factor across different institutional studies for developing resistance has been prior echinocandin exposure. 2, 3, 5 Given the current IDSA guidelines recommending echinocandins for empirical therapy in candidaemia and invasive candidiaisis, a high level of empiric echinocandin usage in the at-risk population will likely lead to increased resistance. The common cited risk factors for invasive candidiasis (broad-spectrum antibiotic usage, renal dialysis, intensive care, total parenteral nutrition etc.) are all present in abundance at our institution. 17 Factors that may have played a role in limiting the development of echinocandin resistance at our institution include a very proactive and aggressive antimicrobial (including antifungal) stewardship programme that discourages excessive and prolonged empirical echinocandin use and exposure, routine availability of echinocandin susceptibility testing, and effective infection prevention measures. We cannot exclude that we may have missed a minor mutation in hotspot 2 that either failed to raise the MIC value or appeared in one of our isolates with elevated MIC values but without a hotspot 1 mutation. However, a prior study that sequenced this region in 77 isolates with decreased susceptibility did not detect a single hotspot 2 mutation.
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In summary, we present data from a large referral regional medical centre, traditionally with a high rate of candidaemia, and have demonstrated not only a declining incidence of candidaemia from 2005 to 2015, similar to that recently reported in Atlanta and Baltimore, 18 but also a low and stable rate of echinocandin resistance in this same group of over 3800 isolates, including C. glabrata. The declining incidence of candidaemia is certainly multifactorial, but we hypothesize that our very low frequency of echinocandin resistance may reflect, in part, an aggressive approach to antimicrobial stewardship (including antifungals) based on emphasizing de-escalation of echinocandin therapy, when appropriate, and limiting the duration of empirical echinocandin use. We are unaware of data from similar institutions with higher rates of echinocandin resistance to allow for this comparison. We suggest that our data support limiting echinocandin exposure as an important intervention towards reducing echinocandin resistance in Candida species.
